A study by the University of Mississippi Medical Center and the Mayo Clinic has revealed that “Troponin” is a predictor for end-stage renal disease and all-cause death. High blood pressure, is a common cardiovascular disease in the U.S., and more than 40 percent of the population will have some form of disease, including hypertension by 2030. End-stage renal disease or end-stage kidney failure often is associated with hypertension and affects approximately 600,000 people at a cost of nearly $50 billion annually.
Troponin is a protein and an increased level of cardiac troponin T (cTnT) in the blood is an early indicator of disease, regardless of race or baseline kidney function.
The study was designed to identify the relationship among genetics, race and hypertension in the community. The research participants consisted of 3,050 patients enrolled in GENOA and the scientists conducted follow-up assessments of death and end-stage kidney failure events nearly 10 to 12 years later. Mayo Clinic researchers studied patients from racial groups using blood samples from people enrolled in the Genetic Epidemiology Network of Arteriopathy (GENOA) study between June 1996 and August 2000. In this study, more than 70 percent of patients had hypertension, and all others were from hypertensive families.
“Early intervention and treatment can be key to stopping kidney disease progression and, potentially, preventable death events,” said Dr. Hickson the lead study author. “This study demonstrates for physicians everywhere that we are getting closer toaccurately predicting future disease and death by examining this one marker. This is important, because, as with many diseases, accurate, early detection means we can more quickly recognize and efficiently treat the disease before it fully manifests — potentially improving a patient’s quality and quantity of life.”
“Among the overall cohort, we found that, at 10 years, those with an abnormal cTnT had a high cumulative incidence of death totaling 47 percent, compared to those with a normal cTnT (7.3 percent),” says Dr. Hickson. “In addition, 10 years after the initial testing, the cumulative incidence of end-stage kidney failure was 27 percent among those with an abnormal cTnT, compared to the substantially lower rate found in those with normal cTnT (1.3 percent).” These findings are reassuring and supportive of future investigations into cTnT as an important biomarker for predicting death and kidney failure.
Stephen T. Turner, MD et al. Troponin T as a Predictor of End-Stage Renal Disease and All-Cause Death in African Americans and Whites From Hypertensive Families. Mayo Clinic Proceedings, October 2015 DOI: 10.1016/j.mayocp.2015.08.016